4-cyclopropyl methoxy-5-methoxypyridine-2-carboxylic acid | 166742-39-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-cyclopropyl methoxy-5-methoxypyridine-2-carboxylic acid
• 英文别名: 4-cyclopropylmethoxy-5-methoxypyridine-2-carboxylic acid；4-(cyclopropylmethoxy)-5-methoxypyridine-2-carboxylic acid
• CAS: 166742-39-8
• 化学式: C₁₁H₁₃NO₄
• 分子量: 223.229
• InChiKey: GHLNUVPJMGKGDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  68.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-cyclopropyl methoxy-5-methoxypyridine-2-carboxylic acid 、 3,5-dichloro-1-hydroxypyridin-4-imine 在 4-二甲氨基吡啶 、 1-丙基磷酸酐 、 三乙胺 作用下， 以 乙酸乙酯 为溶剂， 生成 4-(cyclopropylmethoxy)-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-methoxypyridine-2-carboxamide
  参考文献：
  名称：

  [EN] METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-yl)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND CRISTAL FORMS THEREOF
  [FR] PROCÉDÉ DE PRÉPARATION DE FORMES CRISTALLINES DU 4-(CYCLOPROPYLMÉTHOXY)-N-(3,5-DICHLORO-1-OXYDOPYRIDIN-4-YL)-5-MÉTHOXYPYRIDINE-2-CARBOXAMIDE ET SES FORMES CRISTALLINES

  摘要：

  本发明涉及一种制备4-(环丙基甲氧基)-N-(3,5-二氯-1-氧代吡啶-4-基)-5-甲氧基吡啶-2-羧酰胺式(I)晶型的方法，所述晶型被指定为晶型A到I A，以及它们作为药物的用途。

  公开号：

  WO2014083107A1
• 作为产物：
  描述：

  2-(羟基甲基)-5-甲氧基-4(1H)-吡啶酮 在 potassium permanganate 、 水 、 sodium carbonate 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-cyclopropyl methoxy-5-methoxypyridine-2-carboxylic acid
  参考文献：
  名称：

  [EN] METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-yl)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND CRISTAL FORMS THEREOF
  [FR] PROCÉDÉ DE PRÉPARATION DE FORMES CRISTALLINES DU 4-(CYCLOPROPYLMÉTHOXY)-N-(3,5-DICHLORO-1-OXYDOPYRIDIN-4-YL)-5-MÉTHOXYPYRIDINE-2-CARBOXAMIDE ET SES FORMES CRISTALLINES

  摘要：

  本发明涉及一种制备4-(环丙基甲氧基)-N-(3,5-二氯-1-氧代吡啶-4-基)-5-甲氧基吡啶-2-羧酰胺式(I)晶型的方法，所述晶型被指定为晶型A到I A，以及它们作为药物的用途。

  公开号：

  WO2014083107A1

文献信息

• [EN] PROCESS FOR PREPARING 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDO-4-PYRIDYL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE 4-(CYCLOPROPYLMÉTHOXY)-N-(3,5-DICHLORO-1-OXYDO-4-PYRIDYL)-5-MÉTHOXYPYRIDINE-2-CARBOXAMIDE
  申请人：SANOFI SA

  公开号：WO2014083106A1

  公开（公告）日：2014-06-05

  The present invention relates to a novel process for preparing the compound 4-(cyclopropylmethoxy)-N-(3,5-dichloro-l-oxido-4-pyridyl)-5-methoxypyridine-2-carboxamide of formula (1), in base or hydrate form or in the form of pharmaceutically acceptable salts, and also to several novel synthetic intermediates that are useful in this preparation process.

  本发明涉及一种制备化合物4-(环丙基甲氧基)-N-(3,5-二氯-1-氧化-4-吡啶基)-5-甲氧基吡啶-2-甲酰胺的新工艺，其化合物以碱或水合物形式或以药学上可接受的盐的形式存在，此外还涉及几种在制备过程中有用的新合成中间体。
• Compounds as PDE IV and TNF-inhibitors
  申请人：Fenton Garry

  公开号：US20060084809A1

  公开（公告）日：2006-04-20

  This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.

  本发明涉及[含有(di(醚或硫醚)杂环或氟代芳基)化合物]或其N-氧化物或其药学上可接受的盐，该化合物在治疗患有与肿瘤坏死因子（TNF）生产或生理作用过量有害相关的疾病状态的患者中有用，能够抑制TNF的产生或生理作用。本发明范围内的化合物还抑制环磷酸腺苷磷酸二酯酶，并且在治疗与抑制环磷酸腺苷磷酸二酯酶相关的病理条件的疾病状态中有用，这些疾病状态包括炎症和自身免疫性疾病，特别是第四型环磷酸腺苷磷酸二酯酶。因此，本发明涉及它们在抑制TNF和/或环磷酸腺苷磷酸二酯酶方面的药理学用途，包括含有这些化合物的药理学组合物以及它们的制备方法。
• Compounds as PDE IV and TNF Inhibitors
  申请人：FENTON Garry

  公开号：US20080132706A1

  公开（公告）日：2008-06-05

  This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.

  本发明涉及一种[含有(di(醚或硫醚)杂环或氟取代芳基)化合物或其N-氧化物或其药学上可接受的盐]，其在治疗患有与肿瘤坏死因子(TNF)生理有害过量相关的疾病状态的患者中，有用于抑制TNF的产生或生理效应。本发明范围内的化合物还抑制环磷酸腺苷磷酸二酯酶，并且在治疗与抑制环磷酸腺苷磷酸二酯酶相关的病理条件的疾病状态中有用，这些疾病状态包括炎症和自身免疫性疾病，特别是第四型环磷酸腺苷磷酸二酯酶。因此，本发明涉及它们的药理用途，用于抑制TNF和/或环磷酸腺苷磷酸二酯酶，包括含有这些化合物的药理组合物和其制备方法。
• METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-YL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND CRISTAL FORMS THEREOF
  申请人：SANOFI

  公开号：US20150322014A1

  公开（公告）日：2015-11-12

  The present invention relates to a process of preparation of Crystal Forms of 4-(cyclopropylmethoxy)-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-methoxypyridine-2-carboxamide of formula (I), said Crystal Forms which are designated as Crystal Forms A to I A and their use as a medicament.

  本发明涉及一种制备4-(环丙基甲氧基)-N-(3,5-二氯-1-氧代吡啶-4-基)-5-甲氧基吡啶-2-羧酰胺的晶体形态的过程，所述晶体形态被指定为晶体形态A到I A，并且它们的用途作为药物。
• COMPOUNDS AS PDE IV AND TNF INHIBITORS
  申请人：RHONE-POULENC RORER LIMITED

  公开号：EP0711282A1

  公开（公告）日：1996-05-15